Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.

Juanita Lopez,Rebecca Kristeleit,R. Rulach,Noor Md Haris,Mariana Scaranti,Paul Mulholland,Donna Crawford,Saira Bashir,Caterina Aversa,Alison L. Hannah,Stephanie Anderson,Marc Engelhardt,Thomas Kaindl,Patrice Larger,Phil McKernan,T.R. Jeffry Evans,Elizabeth Ruth Plummer

Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.

2019

Juanita Lopez
Rebecca Kristeleit
R. Rulach
Noor Md Haris
Mariana Scaranti
Paul Mulholland
Donna Crawford
Saira Bashir
Caterina Aversa
Alison L. Hannah
Stephanie Anderson
Marc Engelhardt
Thomas Kaindl
Patrice Larger
Phil McKernan
T.R. Jeffry Evans
Elizabeth Ruth Plummer

2025Background: BAL101553 (prodrug of BAL27862) is a novel TCC that promotes tumor cell death by modulating the spindle assembly checkpoint. BAL27862 is a lipophilic, small molecule shown in rodent...

Keywords:

Glioblastoma
Oncology
Pathology
High-Grade Glioma
Medicine
Internal medicine
once daily
Spindle checkpoint
Prodrug
Cancer research
adult patients
tumor cell death
recurrent glioblastoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations